论文部分内容阅读
目的探讨托拉塞米治疗肝硬化顽固性腹水的临床疗效,为治疗肝硬化顽固性腹水提供参考。方法回顾性分析2013年1月~2014年7月在该院消化内科治疗的52例顽固性腹水患者的临床资料,根据利尿药物的不同将52例患者分为两组,每组26例。观察组在常规治疗的基础上给予托拉塞米进行治疗,对照组在常规治疗的基础上采取呋塞米进行治疗,两组患者都以15d为1个疗程,观察两组患者的24h平均尿量及治疗前后的腹围变化。结果观察组用药5d,10d,15d的24h平均尿量明显高于对照组,差异有统计学意义(P<0.01)。两组患者治疗前平均腹围比较,差异无统计学意义(P>0.05)。治疗15d后,观察组的平均腹围明显低于对照组,t=2.0924,P<0.01为差异有统计学意义。结论可明显增加肝硬化顽固性腹水的尿量,缩小患者的腹围。
Objective To investigate the clinical efficacy of torsemide in the treatment of refractory ascites due to cirrhosis and provide a reference for the treatment of refractory ascites due to liver cirrhosis. Methods The clinical data of 52 patients with refractory ascites admitted to our hospital from January 2013 to July 2014 were retrospectively analyzed. According to the different diuretic drugs, 52 patients were divided into two groups (n = 26 in each group). The observation group was treated with torsemide on the basis of routine treatment, while the control group was treated with furosemide on the basis of routine treatment. Both groups took 15 days as a course of treatment and observed the average 24h urine Volume and abdominal circumference before and after treatment changes. Results The average urine output of the observation group at 5d, 10d and 15d was significantly higher than that of the control group (P <0.01). There was no significant difference between the two groups in mean abdominal circumference before treatment (P> 0.05). After 15 days of treatment, the average abdominal circumference of the observation group was significantly lower than that of the control group, t = 2.0924, P <0.01 for the difference was statistically significant. Conclusions can significantly increase the urine of patients with cirrhosis and refractory ascites, reduce the patient’s abdominal circumference.